AbbVie Contract Manufacturing offers Hot Melt Extrusion (HME) technology that enhances the bioavailability of poorly soluble APIs. In this case study, learn about how AbbVie Contract Manufacturing leveraged Hot Melt Extrusion to improve bioavailability, reduce pill burden, and increase shelf life of an existing formulation.
A pharmaceutical company launched a first-generation non-HME capsule formulation of a drug with a substantial dose that required storage under refrigeration. The company initiated a partnership with AbbVie CMO with the goal of developing a second-generation amorphous solid dispersion (ASD) tablet formulation. That would allow them to increase both drug load and bioavailability, thus reducing pill burden.
AbbVie applied its stage-based approach to determine the applicability of HME for this poorly soluble drug substance Using Hot Melt Extrusion, AbbVie reformulated the drug with improvements including a 20% reduction in drug dosage, 70% reduced pill burden, doubled shelf life, and more.
Download our Hot Melt Extrusion Case Study to learn about our strategies for improving patient experience with this second-generation tablet formulation, with details on every stage from Formulation Development to Commercial Manufacturing.